Skip to main content
NOVT logo

NOVT · Novanta Inc

Track NOVT — free
$117.89 +2.56 (+2.22%) At close · Nov 18
Market Cap
$4.46B
Shares
37.82M
Volume · Nov 18 456.34K Avg daily vol (3M) 441.37K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$117.89 Open$114.56 Day$113.16–118.95 52W close$99.22–168.75 Avg vol 30d544K Short int5.2M · 13.9% of shares · 14.8d Short vol59% Last earningsNov 10, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks
call held May 12, 2026

Latest documents

2026
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Oct 2
Revenue rises 23.1% as Riverpoint Medical acquisition weighs on operating income

Novanta’s quarterly revenue rose 23.1% to $305.0 million, but operating income fell 36.3% to $13.9 million, as acquisition-related costs increased. Novanta completed the Riverpoint Medical acquisition for $1,200.6 million upfront, plus a $250.0 million milestone payment.

Revenue $305.01M ▲ 23.1% Net income $2.02M ▼ 81.1% Diluted EPS $0.05 ▼ 83.3%
Read from the MD&A section
3 source passages
Total revenue of $305.0 million for the three months ended October 2, 2026 increased $57.2 million, or 23.1%, from the prior year period primarily due to revenue from the 2026 acquisition and a 16.0% increase in revenue in the Automation Enabling Technologies segment and 3.5% increase in the Medical Solutions segment excluding the impact of our 2026 acquisition. Operating income of $13.9 million for the three months ended October 2, 2026 decreased $7.9 million, or 36.3%, from the prior year period. This decrease was attributable to an increase in restructuring, acquisition, and related costs of $16.4 million, an increase in amortization expense of $7.8 million, an increase in selling, general, and administrative expenses of $6.2 million, and an increase in research and development, and engineering expenses of $2.3 million, partially offset by an increase in gross profit of $24.7 million. On July 23, 2026, we completed the acquisition of all outstanding equity interests of the parent company of Riverpoint Medical for total upfront cash consideration of $1,200.6 million, net of cash acquired, subject to customary closing and net working capital adjustments. In addition, the agreement provides for a milestone payment of $250.0 million payable on or before January 8, 2027. Open the document at this passage
Nov 9
Current report 8-K
Revenue and Adjusted EBITDA rise, full-year outlook maintained

Novanta reported third-quarter GAAP revenue of $305 million, up 23%, while Adjusted EBITDA rose 38% to $80 million. It expects full-year 2026 GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.

Financial results
3 source passages
- Third Quarter 2026 GAAP Revenue increased 23% to $305 million - Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted EBITDA increased 38% to $80 million For the full year 2026, the Company now expects GAAP revenue to be in the range of $1,135 million to $1,140 million, reflecting reported growth of approximately 16%. The company expects Adjusted EBITDA to be in the range of $274 million to $277 million, and Adjusted Diluted EPS to be in the range of $3.66 to $3.71 per diluted share, or 11% to 13% growth. Open the document at this passage
Oct 2
Current report 8-K/A Events of Jul 22
Current report

Novanta Inc. completed its acquisition of Runway Buyer, LLC on July 23, 2026 for approximately $1.2 billion in cash, plus a $250.0 million milestone payment due on or before January 8, 2027. Runway Buyer reported 2025 revenue of $136,120,000 and net income of 11,462,563.

Read from the first part of this long document
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jul 3
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $265.81M ▲ 10.3% Net income $12.54M ▲ 178.9% Diluted EPS $0.30 ▲ 150.0%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.09B
Trailing 12 months
Net income (TTM)
$53.13M
Trailing 12 months
Revenue growth YoY
+23.1%
Year over year
Operating margin
7.8%
Trailing 12 months
P / E (TTM)
89.3
Trailing earnings · reciprocal yield 1.1%
FCF yield
3.1%
TTM · current market cap
Return on invested capital
2.8%
Trailing 12 months
Net cash
−$680.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.5%
Year over year · more shares
Price change (1Y)
+18.4%
Trailing year
Short interest
13.9%
Latest settlement · 14.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −17%
below
Price vs 50-day avg −15%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 27%
mid-range
Momentum
relative strength
Very Weak
1-month return −16%
trailing
6-month return −26%
trailing
YTD return −1%
this year
Relative strength −23%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $138 › 200d $142 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +43 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.88% of shares out · ▲ +0.2% MoM · 14.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
403 holders — mid 3-yr range
Squeeze score 76
high risk · 0–100
Fundamentals
Strong
Revenue growth +35%
Y/Y
Gross margin 84%
contracting
EPS growth −17%
Y/Y
Free cash flow $48.4M
Valuation P/E 89.3
rich
Buyback $191.6M
remaining
Balance sheet $130.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 51%
annualized · 1-yr
Max drawdown −32%
past year
ATR 6.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 8
Latest guidance · from the 8-K filed Nov 9, 2026
full year 2026
Organic Revenue Growth 7%
Reported revenue growth 16%
Growth in Adjusted EBITDA at least 24%
Operating cash flow Raised $200M
Feb 24, 2026 $145M – $185M changed to Nov 9, 2026 $200M
GAAP revenue Raised $1.14B – $1.14B
Aug 5, 2026 $1.13B – $1.14B changed to Nov 9, 2026 $1.14B – $1.14B
prior FY $980.6M midpoint +16.0% Y/Y
Reported growth 16%
Adjusted EBITDA Maintained $274M – $277M
Aug 5, 2026 $273M – $278M changed to Nov 9, 2026 $274M – $277M
Adjusted Diluted EPS Lowered $3.66 – $3.71
Aug 5, 2026 $3.68 – $3.74 changed to Nov 9, 2026 $3.66 – $3.71
2027
Reported revenue growth at least 15%
fourth quarter of 2026
GAAP revenue $306M – $312M
prior qtr $305.01M midpoint +1.3% QoQ
Reported revenue growth at least 18%
Adjusted EBITDA $76M – $79M
Adjusted Diluted EPS $0.91 – $0.96
Previous outlook earlier release · from the Earnings Call filed Feb 24, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted gross margin · full year 2026 47%
R&D and SG&A expenses · full year 2026 $294M – $298M
Non-GAAP tax rate · full year 2026 21%
Prior guidance period ended · from the 8-K filed Aug 5, 2026
GAAP revenue · third quarter of 2026 $300M – $304M
Adjusted EBITDA · third quarter of 2026 $74M – $77M
Adjusted Diluted EPS · third quarter of 2026 $0.95 – $1.00
Guided vs delivered · last 8 settled
GAAP revenue third quarter of 2026
guided $300M – $304M
$305.01M Beat +1.0%
GAAP revenue second quarter of 2026
guided $259M – $264M
$265.81M Beat +1.6%
Diluted earnings per share second quarter
guided $0.81 – $0.86
$0.30 Miss −64.1%
GAAP revenues first quarter 2026
guided $250M – $255M
$257.71M Beat +2.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−17% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
27% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $138 › 200d $142 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +43 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.88% of shares out · ▲ +0.2% MoM · 14.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
403 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $99 Now $118 · 27% Range high $169
vs 200-day avg -17% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
GAAP → non-GAAP reconciliation
GAAP Diluted EPS $0.05
+$1 Total non-GAAP adjustments
= Adjusted Diluted EPS $1.05
GAAP → non-GAAP reconciliation
GAAP Operating Income 13.91M
+21.41M Amortization of intangible assets
+3.87M Restructuring costs
+19.22M Acquisition and related costs
+800K Inventory acquisition fair value adjustments
+3.69M Planning and design phase of the financial and operation system implementation
+921K Operational transformation costs
+1.05M EU medical device regulation charges
+221K Costs incurred for insurance recovery claim
= Adjusted Operating Income 65.08M
backlog $543M Third quarter 2026 —
Net Debt (Non-GAAP) non-GAAP $689.42M October 2, 2026 —
GAAP → non-GAAP reconciliation
GAAP Total Debt (GAAP) 829.83M
+8.81M Plus: Deferred financing costs
-149.22M Less: Cash and cash equivalents
= Net Debt (Non-GAAP) 689.42M
Adjusted Gross Margin non-GAAP 47% Q2 2026 —
Adjusted Gross Profit (Non-GAAP) non-GAAP $125.1M Three Months Ended July 3, 2026 —
Adjusted Gross Profit Margin (Non-GAAP) non-GAAP 47.1% Three Months Ended July 3, 2026 —
Adjusted Net Income (Non-GAAP) non-GAAP $36.53M Three Months Ended July 3, 2026 —
Adjusted Operating Margin (Non-GAAP) non-GAAP 17.9% Three Months Ended July 3, 2026 —
Free Cash Flow (Non-GAAP) non-GAAP $57.47M Three Months Ended July 3, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net Cash Provided by Operating Activities 64.93M
-7.47M Purchases of property, plant and equipment
= Free Cash Flow (Non-GAAP) 57.47M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Scientific & Technical Instruments — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NOVT
Novanta Inc
this stock
$4.46B -0.9% +35.5% 89.3 13.9%
GRMN
Garmin Ltd
$53.86B +37.8% +15.1% 26.9 1.6%
KEYS
Keysight Technologies, Inc.
$48.74B +40.9% +8.0% 39.2 1.3%
COHR
Coherent Corp.
$41.92B +15.3% +19.2% 44.1 5.1%
TDY
Teledyne Technologies Inc
$28.90B +22.9% -4.6% 28.7 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
403
% held
146.1%
Net QoQ
-20.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
470
View
Short & Settlement
Short Interest Rising
Shares short
5.2M
Days to cover
14.8d
Change
+8.6K sh
View
Short Volume
Short vol %
59%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
499
Value
$71.9K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
47.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
May 18, 2026
View
Financials
Financials
Revenue (FY)
$980.6M
Net income (FY)
$53.8M
EPS diluted
$1.47
View
Buybacks
Authorized
$200.0M
Remaining
$191.6M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 9, 2026
This year
17

Novanta’s quarterly revenue rose 23.1% to $305.0 million, but operating income fell 36.3% to $13.9 million, as acquisition-related costs increased. Novanta completed the Riverpoint Medical acquisition for $1,200.6 million upfront, plus a $250.0 million milestone payment.

View
Proposed Sales
Value
$97.9K
Shares
663
Filed
Sep 11, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Novanta to Present at the Jefferi…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
NOVT -4.4% -15.8% -26.0% -19.1% -0.9%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -0.5% -10.2% -22.5% -15.7% -8.0%

Capital returns

Buyback program · as of Oct 2, 2026
Authorized
$200.00M
Spent (derived)
$8.40M
Remaining
$191.60M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1076930 CUSIP 67000B104 13F (30d) 387 filings 356 filers Visit website Investor relations